These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 19011357)

  • 1. [Bowel perforation associated with bevacizumab therapy in recurrent ovarian cancers without bowel obstruction or bowel involvement].
    Takano M; Kikuchi Y; Kato M; Yoshikawa T; Kita T
    Gan To Kagaku Ryoho; 2008 Nov; 35(11):1981-4. PubMed ID: 19011357
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Avoiding bevacizumab related gastrointestinal toxicity for recurrent ovarian cancer by careful patient screening.
    Simpkins F; Belinson JL; Rose PG
    Gynecol Oncol; 2007 Oct; 107(1):118-23. PubMed ID: 17658587
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The risk of gastrointestinal perforation and/or fistula in patients with recurrent ovarian cancer receiving bevacizumab compared to standard chemotherapy: a retrospective cohort study.
    Sfakianos GP; Numnum TM; Halverson CB; Panjeti D; Kendrick JE; Straughn JM
    Gynecol Oncol; 2009 Sep; 114(3):424-6. PubMed ID: 19552944
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Which factors predict bowel complications in patients with recurrent epithelial ovarian cancer being treated with bevacizumab?
    Richardson DL; Backes FJ; Hurt JD; Seamon LG; Copeland LJ; Fowler JM; Cohn DE; O'Malley DM
    Gynecol Oncol; 2010 Jul; 118(1):47-51. PubMed ID: 20382413
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of bevacizumab and pegylated liposomal doxorubicin for the patients with recurrent or refractory ovarian cancers.
    Kudoh K; Takano M; Kouta H; Kikuchi R; Kita T; Miyamoto M; Watanabe A; Kato M; Goto T; Kikuchi Y
    Gynecol Oncol; 2011 Aug; 122(2):233-7. PubMed ID: 21601912
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer.
    Cannistra SA; Matulonis UA; Penson RT; Hambleton J; Dupont J; Mackey H; Douglas J; Burger RA; Armstrong D; Wenham R; McGuire W
    J Clin Oncol; 2007 Nov; 25(33):5180-6. PubMed ID: 18024865
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Incidence and management of bevacizumab-associated gastrointestinal perforations in patients with recurrent ovarian carcinoma.
    Diaz JP; Tew WP; Zivanovic O; Konner J; Sabbatini PJ; dos Santos LA; Abu-Rustum NR; Chi DS; Aghajanian C; Barakat RR
    Gynecol Oncol; 2010 Mar; 116(3):335-9. PubMed ID: 20004956
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bevacizumab in the treatment of ovarian cancer.
    Han ES; Monk BJ
    Expert Rev Anticancer Ther; 2007 Oct; 7(10):1339-45. PubMed ID: 17944559
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bevacizumab, paclitaxel and carboplatin for advanced ovarian cancer: low risk of gastrointestinal and cardiovascular toxicity.
    Abaid LN; Lopez KL; Micha JP; Rettenmaier MA; Brown JV; Goldstein BH
    Eur J Gynaecol Oncol; 2010; 31(3):308-11. PubMed ID: 21077475
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Feasibility of surgery after systemic treatment with the humanized recombinant antibody bevacizumab in heavily pretreated patients with advanced epithelial ovarian cancer.
    Sehouli J; Papanikolaou G; Braicu EI; Pietzner K; Neuhaus P; Fotopoulou C
    Ann Surg Oncol; 2012 Apr; 19(4):1326-33. PubMed ID: 22090022
    [TBL] [Abstract][Full Text] [Related]  

  • 11. What is the risk of bowel perforation associated with bevacizumab therapy in ovarian cancer?
    Han ES; Monk BJ
    Gynecol Oncol; 2007 Apr; 105(1):3-6. PubMed ID: 17383545
    [No Abstract]   [Full Text] [Related]  

  • 12. Bowel perforation from bevacizumab for the treatment of metastatic colon cancer: incidence, etiology, and management.
    Heinzerling JH; Huerta S
    Curr Surg; 2006; 63(5):334-7. PubMed ID: 16971205
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bevacizumab and its use in epithelial ovarian cancer.
    Matulonis UA
    Future Oncol; 2011 Mar; 7(3):365-79. PubMed ID: 21323425
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: The AURELIA open-label randomized phase III trial.
    Pujade-Lauraine E; Hilpert F; Weber B; Reuss A; Poveda A; Kristensen G; Sorio R; Vergote I; Witteveen P; Bamias A; Pereira D; Wimberger P; Oaknin A; Mirza MR; Follana P; Bollag D; Ray-Coquard I
    J Clin Oncol; 2014 May; 32(13):1302-8. PubMed ID: 24637997
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bevacizumab plus low-dose metronomic oral cyclophosphamide in heavily pretreated patients with recurrent ovarian cancer.
    Sánchez-Muñoz A; Mendiola C; Pérez-Ruiz E; Rodríguez-Sánchez CA; Jurado JM; Alonso-Carrión L; Ghanem I; de Velasco G; Quero-Blanco C; Alba E
    Oncology; 2010; 79(1-2):98-104. PubMed ID: 21079407
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bevacizumab in heavily pre-treated and platinum resistant ovarian cancer: a retrospective study of the North-Eastern German Society of Gynaecologic Oncology (NOGGO) Ovarian Cancer Study Group.
    Pietzner K; Richter R; Chekerov R; Erol E; Oskay-Özcelik G; Lichtenegger W; Sehouli J
    Anticancer Res; 2011 Aug; 31(8):2679-82. PubMed ID: 21778323
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical predictors of bevacizumab-associated gastrointestinal perforation.
    Tanyi JL; McCann G; Hagemann AR; Coukos G; Rubin SC; Liao JB; Chu CS
    Gynecol Oncol; 2011 Mar; 120(3):464-9. PubMed ID: 21168199
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bevacizumab and ovarian cancer.
    Sato S; Itamochi H
    Curr Opin Obstet Gynecol; 2012 Feb; 24(1):8-13. PubMed ID: 22123222
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bevacizumab and weekly taxane chemotherapy demonstrates activity in refractory ovarian cancer.
    Cohn DE; Valmadre S; Resnick KE; Eaton LA; Copeland LJ; Fowler JM
    Gynecol Oncol; 2006 Aug; 102(2):134-9. PubMed ID: 16527339
    [TBL] [Abstract][Full Text] [Related]  

  • 20. What is the benefit of bevacizumab combined with chemotherapy in patients with recurrent ovarian, fallopian tube or primary peritoneal malignancies?
    Cheng X; Moroney JW; Levenback CF; Fu S; Jaishuen A; Kavanagh JJ
    J Chemother; 2009 Nov; 21(5):566-72. PubMed ID: 19933049
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.